Metabolic
Bone Disease Secondary Osteoporosis
Osteoporosis may occur as a
secondary problem in patients with a range of endocrine and other disorders
(Fig. 55a; Table 55.1). A high proportion of patients treated chronically with
glucocorticoids develop osteoporosis. It may develop in patients immobilized
for long periods, when bone resorption develops with consequent hypercalciuria
and hypercalcaemia, especially in younger patients in whom bone turnover is
normally rapid. Osteoporosis has been observed in astronauts, presumably due to
the loss of gravitational effects, although the aetiology of this phenomenon is
unknown. Hereditary disorders of collagen expression and metabolism may result
in osteoporosis. These include Ehlers–Danlos syndrome, homocysteinuria and
osteogenesis imperfecta.
The vast majority of patients
with osteoporosis have the primary condition but causes of secondary
osteoporosis should always be sought when undertaking clinical assessment.
Glucocorticoids and
osteoporosis Glucocorticoids,
used to treat inflammatory disorders, cause osteoporosis, affecting
predominantly the trabecular bone of the axial skeleton such that vertebral
fractures are more common than those of the hip. Glucocorticoids cause
osteoporosis through a wide variety of actions (Fig. 55b).
Direct actions. Glucocorticoids directly inhibit the
replication of osteoblast lineages and the biosynthesis of new osteoblast cells
and they induce apoptosis of osteoblasts, partially through their interactions
with growth factors such as the insulin-like growth factors. In addition,
glucocorticoids may directly decrease synthesis of osteocalcin, a component of
bone matrix, and stimulate the synthesis of collagenase-3, which breaks down
collagen types I and II, essential building blocks of bone. Furthermore,
glucocorticoids stimulate osteoclast activity directly, and possibly
indirectly, via secondary hyperparathyroidism.
Indirect actions. Glucocorticoids inhibit calcium absorption
from the GIT and increase renal excretion, which may contrib- ute to the
development of secondary hyperparathyroidism. Glucocorticoids are associated
with decreased plasma levels of estrogens and testosterone by suppressing
adrenocorticotrophic hormone (ACTH) secretion from the anterior pituitary
gland, thus resulting in suppression of adrenal androgen production.
Luteinizing hormone production is decreased with consequent lowering of both
estradiol and testosterone production in women and men respectively. Glucocorticoids
also inhibit growth hormone production. Patients with Cushing’s syndrome, which
is associated with excessive adrenal activity, may also be at risk of
osteoporosis and fractures.
Glucocorticoid therapy is a
major cause of rapid bone loss and primary preventive therapy with
bisphosphonates should be prescribed for every patient about to start a course
of steroid therapy for more than 3 months.
Other endocrine disorders
Hyperthyroidism can cause osteoporosis by the direct
action of thyroid hormone on bone resorption, since thyroid hormone is normally
associated with high bone turnover. Fractures are uncommon in hyperthyroidism
due to prompt diagnosis and treatment. Postmenopausal women with osteoporosis
and a history of hyperthyroidism are, however, at increased risk of hip
fractures. Type 1 diabetes mellitus is associated with mild osteopenia of
cortical bone, although there does not seem to be a high incidence of fractures
in these patients. Patients with Type 2diabetes mellitus, on the other hand, usually
have normal bone mass.